Newark, NJNCT05332002Now EnrollingIRB Ready

Gastro-Intestinal Cancer Clinical Trial in Newark, NJ

Access cutting-edge gastro-intestinal cancer treatment through this clinical trial at a research site in Newark. Study-provided care at no cost to qualified participants.

Sponsored by Rutgers, The State University of New Jersey

Quick Self-Assessment

See if you qualify for this Newark location

Preparing your pre-screening questions…

Expert Care in Newark

Access gastro-intestinal cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related gastro-intestinal cancer treatment provided free

Apply for This Newark Location

Check if you qualify for this gastro-intestinal cancer clinical trial in Newark, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Newark

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Newark site if eligible
  4. 4Begin participation

About This Gastro-Intestinal Cancer Study in Newark

The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.

Sponsor: Rutgers, The State University of New Jersey

Who Can Participate

Inclusion Criteria

Histologically and/or cytologically confirmed metastatic or unresectable adenocarcinoma of esophageal, gastroesophageal junction or gastric origin
Tumor is HER2 negative by standard local testing methodology
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 - 2
Measurable disease by response evaluation criteria in solid tumors (RECIST) v1.1
No prior systemic therapy for the present cancer given in the metastatic setting and \> 6 months from administration of peri-operative chemotherapy, if applicable o Note: up to two prior cycles of mFOLFOX6 for the present illness is permitted if patients otherwise qualify for the study with adequate baseline imaging
At least 18 years of age
Adequate bone marrow and organ functions as defined by:
Absolute neutrophil count ≥ 1500 cells/ μL
Hemoglobin ≥ 8 g/ dL
Platelets \> 100,000 / μL
Creatinine ≤ 1.5 x upper limit of normal (ULN) OR creatinine clearance ≥ 30 mL/min by Cockroft-Gault
Total bilirubin ≤ ULN
Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) \< 2.5 x ULN, unless with liver metastases and then must be \<5 x ULN of normal
Women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect pregnancy on study, she must notify her treating physician immediately.
Ability to understand the nature of this study protocol and give written informed consent.
Willingness and ability to comply with scheduled visits, treatment plans laboratory tests and other study procedures.

Exclusion Criteria

Receipt of any investigational agents at the time of registration
Known, untreated brain metastases
Grade two or greater peripheral neuropathy
Presence of any additional active malignancy within the past three years where the malignancy is at least reasonably likely to later the course of therapy, require systemic therapy or interfere with imaging assessments
For those patients who are going to receive nivolumab
No active use of systemic corticosteroids at the time of enrollment, at a dose equivalent of 10 mg/day or prednisone
Clinically significant autoimmune disease which is active or has required systemic immunosuppression within the last two years
Prior organ transplant or bone marrow transplant
History of interstitial lung disease or pneumonitis
Uncontrolled intercurrent illness, including significant active infection, symptomatic congestive heart failure, unstable angina or active arrhythmia
Major surgery within the four weeks prior to initiation of study treatment
A history of allergy or hypersensitivity to any of the study drugs
Any additional significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from fully participating in the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Newark?

Yes, this clinical trial (NCT05332002) has an active research site in Newark, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Gastro-Intestinal Cancer Treatment Options in Newark, NJ

If you're searching for gastro-intestinal cancer treatment options in Newark, NJ, this clinical trial (NCT05332002) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Newark research site is actively enrolling participants for this clinical trial. You'll receive care from experienced gastro-intestinal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all gastro-intestinal cancer clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Newark, NJ

See all ankylosing spondylitis clinical trials recruiting in Newark — not just this study.

Browse Ankylosing Spondylitis Trials in Newark →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Newark?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Newark, NJ